Meta-analysis of 44 cohorts (52 reports, 1833 patients) of CAR T-cell therapy in multiple myeloma: pooled overall response 88% and complete response 55%. Grade ≥3 neutropenia 83%, CRS 8%, ICANS 3%. Higher extramedullary disease linked to lower response.
Meta-analysisn = 1,833
Lee et al. Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression